Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Forum Dermatologicum
MENU
Shortcuts Submit an article Author Guidelines Ahead Of Print Reviewers 2023

Vol 9, No 2 (2023)
Review paper
Published online: 2023-03-10
Add to basket: 49.00 PLN
Get Citation

Correlation between the components of the metabolic syndrome and psoriasis

Adam Wełniak1, Aleksandra Nowicka1, Rafał Czajkowski2
DOI: 10.5603/FD.a2023.0007
·
Forum Dermatologicum 2023;9(2):56-60.
Affiliations
  1. Student’s Scientific Circle of Dermatology, Department of Dermatology and Venerology Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Poland
  2. Department of Dermatology and Venerology Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Poland

paid access

Vol 9, No 2 (2023)
REVIEW ARTICLES
Published online: 2023-03-10

Abstract

Psoriasis (Ps) is a chronic inflammatory skin condition affecting 2% of the world’s population. These people have a higher risk of developing metabolic syndrome (MS) up to one-third of patients. According to current criteria, the diagnosis of MS is made on the basis of a diagnosis of obesity and two out of three: elevated blood pressure, abnormal glucose metabolism, or atherogenic dyslipidemia. The correlation between the MS and Ps is probably due to shared genetic factors; the expression of common genes leads to the development of both diseases. Moreover, in the course of Ps, there is systemic inflammation that prompts the development of components of the MS. The psoriatic lesions negatively affect the patient’s well-being leading to social withdrawal and diminishing tendency to exercise, directing to overweight and hypertension independently of the systemic inflammation. Current evidence suggests that the development of Ps is most influenced by obesity, but the risk of development is greatest when all elements of the MS are present. Appropriate prevention and lifestyle changes are important, as they significantly reduce the risk of developing MS and minimize the symptoms of Ps, while also reducing the cardiovascular risk which both diseases lead to its increment independently.

Abstract

Psoriasis (Ps) is a chronic inflammatory skin condition affecting 2% of the world’s population. These people have a higher risk of developing metabolic syndrome (MS) up to one-third of patients. According to current criteria, the diagnosis of MS is made on the basis of a diagnosis of obesity and two out of three: elevated blood pressure, abnormal glucose metabolism, or atherogenic dyslipidemia. The correlation between the MS and Ps is probably due to shared genetic factors; the expression of common genes leads to the development of both diseases. Moreover, in the course of Ps, there is systemic inflammation that prompts the development of components of the MS. The psoriatic lesions negatively affect the patient’s well-being leading to social withdrawal and diminishing tendency to exercise, directing to overweight and hypertension independently of the systemic inflammation. Current evidence suggests that the development of Ps is most influenced by obesity, but the risk of development is greatest when all elements of the MS are present. Appropriate prevention and lifestyle changes are important, as they significantly reduce the risk of developing MS and minimize the symptoms of Ps, while also reducing the cardiovascular risk which both diseases lead to its increment independently.

Full Text:

Add to basket: 49.00 PLN
Get Citation

Keywords

psoriasis, metabolic syndrome, obesity, hyperglycemia, hypertension

About this article
Title

Correlation between the components of the metabolic syndrome and psoriasis

Journal

Forum Dermatologicum

Issue

Vol 9, No 2 (2023)

Article type

Review paper

Pages

56-60

Published online

2023-03-10

Page views

2406

Article views/downloads

36

DOI

10.5603/FD.a2023.0007

Bibliographic record

Forum Dermatologicum 2023;9(2):56-60.

Keywords

psoriasis
metabolic syndrome
obesity
hyperglycemia
hypertension

Authors

Adam Wełniak
Aleksandra Nowicka
Rafał Czajkowski

References (50)
  1. Fu Y, Lee CH, Chi CC. Association of psoriasis with inflammatory bowel disease: a systematic review and meta-analysis. JAMA Dermatol. 2018; 154(12): 1417–1423.
    CrossRefPubMed
  2. Korkmaz S, Güçlü H, Hatipoğlu EŞ, et al. Metabolic syndrome may exacerbate macular and retinal damage in psoriasis vulgaris. Ocul Immunol Inflamm. 2019; 27(5): 798–804.
    CrossRefPubMed
  3. Tas B, Kabeloglu V. Prevalence of metabolic syndrome and its parameters and their correlations with psoriasis duration, severity, and sleep quality in psoriasis patients: a cross-sectional study. Dermatol Pract Concept. 2021; 11(3): e2021049.
    CrossRefPubMed
  4. Fernández-Armenteros JM, Gómez-Arbonés X, Buti-Soler M, et al. Psoriasis, metabolic syndrome and cardiovascular risk factors. A population-based study. J Eur Acad Dermatol Venereol. 2019; 33(1): 128–135.
    CrossRefPubMed
  5. Polic MV, Miskulin M, Smolic M, et al. Psoriasis severity-a risk factor of insulin resistance independent of metabolic syndrome. Int J Environ Res Public Health. 2018; 15(7): 1486.
    CrossRefPubMed
  6. Wen S, Liu C, Li Y, et al. Psoriasis exacerbates the state of insulin resistance in patients with type 2 diabetes. Diabetes Metab Syndr Obes. 2021; 26(14): 2389–2397.
    CrossRefPubMed
  7. Brazzelli V, Maffioli P, Bolcato V, et al. Psoriasis and diabetes, a dangerous association: evaluation of insulin resistance, lipid abnormalities, and cardiovascular risk biomarkers. Front Med (Lausanne). 2021; 23(8): 605691.
    CrossRefPubMed
  8. Miao C, Li J, Li Y, et al. Obesity and dyslipidemia in patients with psoriasis: A case-control study. Medicine (Baltimore). 2019; 98(31): e16323.
    CrossRefPubMed
  9. Botelho KP, Pontes MA, Rodrigues CE, et al. Prevalence of metabolic syndrome among patients with psoriasis treated with TNF inhibitors and the effects of anti-tnf therapy on their lipid profile: a prospective cohort study. Metab Syndr Relat Disord. 2020; 18(3): 154–160.
    CrossRefPubMed
  10. Holmannova D, Borska L, Andrys C, et al. The impact of psoriasis and metabolic syndrome on the systemic inflammation and oxidative damage to nucleic acids. J Immunol Res. 2020: 7352637.
    CrossRefPubMed
  11. Snekvik I, Nilsen TIL, Romundstad PR, et al. Metabolic syndrome and risk of incident psoriasis: prospective data from the HUNT Study, Norway. Br J Dermatol. 2019; 180(1): 94–99.
    CrossRefPubMed
  12. Budu-Aggrey A, Brumpton B, Tyrrell J, et al. Evidence of a causal relationship between body mass index and psoriasis: A mendelian randomization study. PLoS Med. 2019; 16(1): e1002739.
    CrossRefPubMed
  13. Adışen E, Uzun S, Erduran F, et al. Prevalence of smoking, alcohol consumption and metabolic syndrome in patients with psoriasis. An Bras Dermatol. 2018; 93(2): 205–211.
    CrossRefPubMed
  14. Dobrowolski P, Prejbisz A, Kuryłowicz A, et al. Metabolic syndrome — a new definition and management guidelines. Arterial Hypertension. 2022; 26(3): 99–121.
    CrossRef
  15. Kyriakou A, Patsatsi A, Sotiriadis D, et al. Serum leptin, resistin, and adiponectin concentrations in psoriasis: a meta-analysis of observational studies. Dermatology. 2017; 233(5): 378–389.
    CrossRefPubMed
  16. Gable DR, Hurel SJ, Humphries SE. Adiponectin and its gene variants as risk factors for insulin resistance, the metabolic syndrome and cardiovascular disease. Atherosclerosis. 2006; 188(2): 231–244.
    CrossRefPubMed
  17. Kim HN, Han K, Park YG, et al. Metabolic syndrome is associated with an increased risk of psoriasis: A nationwide population-based study. Metabolism. 2019; 99: 19–24.
    CrossRefPubMed
  18. Sondermann W, Djeudeu Deudjui DA, Körber A, et al. Psoriasis, cardiovascular risk factors and metabolic disorders: sex-specific findings of a population-based study. J Eur Acad Dermatol Venereol. 2020; 34(4): 779–786.
    CrossRefPubMed
  19. Amin M, Lee EB, Bhutani T, et al. Do psoriasis patients engage in vigorous physical activity? Cutis. 2018; 101(3): 198–200.
    PubMed
  20. Ko SH, Chi CC, Yeh ML, et al. Lifestyle changes for treating psoriasis. Cochrane Database Syst Rev. 2019; 7(7): CD011972.
    CrossRefPubMed
  21. Alotaibi HA. Effects of weight loss on psoriasis: a review of clinical trials. Cureus. 2018; 10(10): e3491.
    CrossRefPubMed
  22. Chi CC, Lee CY, Liu CY, et al. Effects of antidiabetic drugs on psoriasis: A meta-analysis. Eur J Clin Invest. 2021; 51(2): e13377.
    CrossRefPubMed
  23. Patrick MT, Stuart PE, Zhang H, et al. Causal relationship and shared genetic loci between psoriasis and type 2 diabetes through trans-disease meta-analysis. J Invest Dermatol. 2021; 141(6): 1493–1502.
    CrossRefPubMed
  24. Polic MV, Miskulin M, Smolic M, et al. Psoriasis severity-a risk factor of insulin resistance independent of metabolic syndrome. Int J Environ Res Public Health. 2018; 15(7): 1486.
    CrossRefPubMed
  25. Patrick MT, Stuart PE, Zhang H, et al. Causal relationship and shared genetic loci between psoriasis and type 2 diabetes through trans-disease meta-analysis. J Invest Dermatol. 2021; 141(6): 1493–1502.
    CrossRefPubMed
  26. Wang H, Wang Z, Rani PL, et al. Identification of PTPN22, ST6GAL1 and JAZF1 as psoriasis risk genes demonstrates shared pathogenesis between psoriasis and diabetes. Exp Dermatol. 2017; 26(11): 1112–1117.
    CrossRefPubMed
  27. Ikumi K, Odanaka M, Shime H, et al. Hyperglycemia is associated with psoriatic inflammation in both humans and mice. J Invest Dermatol. 2019; 139(6): 1329–1338.e7.
    CrossRefPubMed
  28. Chi CC, Lee CY, Liu CY, et al. Effects of antidiabetic drugs on psoriasis: A meta-analysis. Eur J Clin Invest. 2021; 51(2): e13377.
    CrossRefPubMed
  29. Kim HN, Han K, Song SW, et al. Hypertension and risk of psoriasis incidence: An 11-year nationwide population-based cohort study. PLoS One. 2018; 13(8): e0202854.
    CrossRefPubMed
  30. Svanström C, Lonne-Rahm SB, Nordlind K. Psoriasis and alcohol. Psoriasis (Auckl). 2019; 9: 75–79.
    CrossRefPubMed
  31. ElGhareeb MI, Khater MH, Fakhr A, et al. Risk and severity of psoriasis vulgaris in relation to angiotensin II type 1 receptor gene polymorphism and metabolic syndrome. Clin Cosmet Investig Dermatol. 2019; 12: 683–690.
    CrossRefPubMed
  32. Duan Xi, Liu J, Mu Y, et al. A systematic review and meta-analysis of the association between psoriasis and hypertension with adjustment for covariates. Medicine (Baltimore). 2020; 99(9): e19303.
    CrossRefPubMed
  33. Kim HN, Han K, Song SW, et al. Hypertension and risk of psoriasis incidence: An 11-year nationwide population-based cohort study. PLoS One. 2018; 13(8): e0202854.
    CrossRefPubMed
  34. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of bood cholesterol: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019; 139(25): e1082–e1143; Erratum in: Circulation. 2019 Jun 18;139(25):e1182-e1186.
    CrossRefPubMed
  35. Morici N, Ferri LA, Alicandro G, et al. Psoriasis and the risk of acute coronary syndrome in the elderly. Int J Cardiol. 2018; 273: 44–46.
    CrossRefPubMed
  36. Yazdanpanah MJ, Vahabi-Amlashi S, Nematy M, et al. Association of serum lipid profiles and dietary intakes of vitamin E and fiber with psoriasis severity. Caspian J Intern Med. 2021; 12(4): 606–612.
    CrossRefPubMed
  37. Sobhan M, Seif Rabiei MA, Amerifar M. Correlation between lipid profile and acne vulgaris. Clin Cosmet Investig Dermatol. 2020; 13: 67–71.
    CrossRefPubMed
  38. Trakaki A, Marsche G. High-Density lipoprotein (HDL) in allergy and skin diseases: focus on immunomodulating functions. Biomedicines. 2020; 8(12): 558.
    CrossRefPubMed
  39. Lai CQ, Parnell LD, Smith CE, et al. Carbohydrate and fat intake associated with risk of metabolic diseases through epigenetics of CPT1A. Am J Clin Nutr. 2020; 112(5): 1200–1211.
    CrossRefPubMed
  40. Li YY, Zhou YH, Gong Ge, et al. LPL gene Pvu II polymorphism and hypertriglyceridemia: a meta-analysis involving 1,640 subjects. Korean J Intern Med. 2017; 32(6): 1018–1024.
    CrossRefPubMed
  41. Girisha BS, Thomas N. Metabolic syndrome in psoriasis among Urban South Indians: a case control study using SAM-NCEP criteria. J Clin Diagn Res. 2017; 11(2): WC01–WC04.
    CrossRefPubMed
  42. Tollefson MM, Van Houten HK, Asante D, et al. Association of psoriasis with comorbidity development in children with psoriasis. JAMA Dermatol. 2018; 154(3): 286–292.
    CrossRefPubMed
  43. Paiva-Lopes MJ, Delgado Alves J. Psoriasis-associated vascular disease: the role of HDL. J Biomed Sci. 2017; 24(1): 73.
    CrossRefPubMed
  44. Ferraz-Amaro I, Hernández-Hernández MV, Armas-González E, et al. HDL cholesterol efflux capacity is related to disease activity in psoriatic arthritis patients. Clin Rheumatol. 2020; 39(6): 1871–1880.
    CrossRefPubMed
  45. Ajala ON, Demler OV, Liu Y, et al. Anti-Inflammatory HDL function, incident cardiovascular events, and mortality: a secondary analysis of the JUPITER randomized clinical trial. J Am Heart Assoc. 2020; 9(17): e016507.
    CrossRefPubMed
  46. Socha M, Pietrzak A, Grywalska E, et al. The effect of statins on psoriasis severity: a meta-analysis of randomized clinical trials. Arch Med Sci. 2020; 16(1): 1–7.
    CrossRefPubMed
  47. Fisher DA, Elias PM, LeBoit PL. Exacerbation of psoriasis by the hypolipidemic agent, gemfibrozil. Arch Dermatol. 1988; 124(6): 854–855.
    PubMed
  48. Masson W, Lobo M, Molinero G, et al. Should all patients with psoriasis receive statins? Analysis according to different strategies. An Bras Dermatol. 2019; 94(6): 691–697.
    CrossRefPubMed
  49. Wełniak A, Gryczka K, Kędziora-Kornatowska K. Stratification and management of cardiovascular risk among patients with psoriasis. J Health Study Med. 2021(4): 5–26.
    CrossRef
  50. Nowowiejska J, Baran A, Flisiak I. Psoriasis and cardiometabolic disorders. Dermatology Review. 2020; 107(6): 508–520.
    CrossRef

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
phone: +48 58 320 94 94, fax: +48 58 320 94 60, e-mail: viamedica@viamedica.pl